💊 GLP-1 Drugs
Semaglutide Cardiovascular Benefits — SELECT Trial Explained (2026)
The SELECT trial showed semaglutide reduces cardiovascular events by 20% in non-diabetics with obesity. What this means for prescribing and who qualifies. Updated January 2026.
Key Takeaways
- SELECT trial: semaglutide reduced major cardiovascular events by 20% in non-diabetics
- This is the first approved drug for CVD risk reduction in obesity without diabetes
- The benefit appeared within 3 months — earlier than weight loss could explain
- 17,604 participants — one of the largest cardiovascular drug trials ever conducted
- In the UK, this opened NHS access to Wegovy for patients with BMI ≥30 + established CVD
The SELECT Trial — What It Found
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was published in the New England Journal of Medicine in November 2023. It enrolled 17,604 adults with pre-existing cardiovascular disease, overweight/obesity, but without Type 2 diabetes — and followed them for 3.3 years.
20%
Reduction in major cardiovascular events (MACE)
17,604
Participants — one of the largest CV drug trials
3.3 yrs
Average follow-up duration
SELECT Trial Results in Detail
| Outcome | Semaglutide | Placebo | Reduction |
|---|---|---|---|
| Primary MACE (CV death/MI/stroke) | 6.5% | 8.0% | 20% (HR 0.80) |
| Cardiovascular death | 2.5% | 3.0% | 15% |
| Non-fatal MI | 3.8% | 4.8% | 28% |
| Non-fatal stroke | 1.7% | 2.1% | 7% (NS) |
| Heart failure hospitalisation | 1.7% | 2.0% | 18% |
| All-cause mortality | 2.9% | 3.3% | 19% |
Why the Benefit Goes Beyond Weight Loss
Critically, the cardiovascular benefit in SELECT appeared within the first 90 days — before meaningful weight loss had occurred. This strongly suggests direct cardiovascular effects of semaglutide beyond weight reduction:
- Anti-inflammatory effects: Direct reduction in CRP, IL-6, and other inflammatory markers
- Blood pressure reduction: Average 3–4 mmHg systolic reduction
- Improved lipid profile: LDL reduction, triglyceride reduction
- Improved arterial function: Reduced arterial stiffness and improved endothelial function
- Anti-atherosclerotic effects: Direct stabilisation of atherosclerotic plaques
What This Means for Prescribing
Based on SELECT, regulatory agencies made landmark decisions:
- FDA (USA, March 2024): Approved Wegovy for cardiovascular event risk reduction in adults with established CVD + overweight/obesity
- NICE/NHS (UK, 2024): Added BMI ≥30 + established CVD as a Wegovy access pathway, alongside the existing obesity pathway
- ESC/AHA guidelines: Updated to include semaglutide as a cardiovascular risk reduction agent in appropriate patients
🔢 Free Tool
Blood Pressure Checker
Get personalised results based on your own data.
Open Free Calculator →Frequently Asked Questions
Who qualifies for Wegovy based on cardiovascular risk?▼
In the USA, FDA approval covers adults with established CVD (history of heart attack, stroke, or peripheral arterial disease) + BMI ≥27. In the UK, NICE allows Wegovy for BMI ≥30 + established CVD as a prescribing pathway. Both require specialist prescribing in the current rollout.
Does tirzepatide also reduce cardiovascular events?▼
SURMOUNT-MMO (the tirzepatide cardiovascular outcomes trial) is currently ongoing. Based on the cardiometabolic improvements seen with tirzepatide, the expectation is positive results — but the evidence is not yet available. Semaglutide currently has the only proven cardiovascular outcome data for GLP-1 drugs in non-diabetics.
How long do you need to take semaglutide for cardiovascular benefit?▼
In SELECT, benefits accrued over 3.3 years with continued use. The cardiovascular event reduction began within 3 months and continued to grow throughout follow-up. Like statins, semaglutide for cardiovascular risk reduction is a long-term treatment — the benefit is maintained only with ongoing use.
Related Health Guides
Article
Wegovy Complete Guide
Article
Mounjaro vs Ozempic
Article
Heart Failure Treatment
Calculator
Blood Pressure Checker
⚕️ Medical Disclaimer: For informational purposes only. Always consult a qualified healthcare professional before starting or changing any medication or treatment.
JO
Consultant Cardiologist
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.